Related Experiment Videos
Autocrine growth regulation in neuroectodermal tumors as detected with oligodeoxynucleotide antisense molecules
Abstract:
The cell lines of three neuroectodermal tumors, two glioblastomas (HTZ-146, HTZ-17) and one melanoma (HTZ-19) were established and screened for the expression of growth factors by northern blotting and immunochemical methods. All three tumors were positive for platelet-derived growth factor- (PDGF-) A-, -B-chain, and basic fibroblast growth factor (bFGF) messenger ribonucleic acids. Cultured cells as well as original tumor material were also positive for PDGF-AA-, PDGF-BB, and bFGF protein, as shown by immunochemistry. To investigate the possible pathophysiological role of PDGF and bFGF, antisense technology was employed with chemically modified nuclease-stable 14-mer phosphorothioate oligodeoxynucleotides. Proliferation of all three tumors was reduced to a different extent with antisense phosphorothioate oligodeoxynucleotides in vitro, targeted against PDGF-A-chain-, -B-chain-, and -bFGF-messenger ribonucleic acid. These data indicate autocrine stimulatory loops for PDGF and bFGF, which may be blocked, may have different relevance in neuroectodermal tumors in vitro, and may have conceivable future therapeutic implications.
Insights
Neuroectodermal tumors, including glioblastomas and melanoma, express platelet-derived growth factor (PDGF) and basic fibroblast growth factor (bFGF). Inhibiting these growth factors with antisense technology reduced tumor cell proliferation in vitro.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Neuroectodermal tumors, such as glioblastomas and melanomas, are complex malignancies.
- Growth factors play a critical role in tumor development and progression.
Purpose of the Study:
- To investigate the expression and role of platelet-derived growth factor (PDGF) and basic fibroblast growth factor (bFGF) in neuroectodermal tumors.
- To explore the potential of targeting these growth factors for therapeutic intervention.
Main Methods:
- Established cell lines from three neuroectodermal tumors (two glioblastomas, one melanoma).
- Utilized Northern blotting and immunochemistry to detect PDGF and bFGF messenger ribonucleic acids (mRNAs) and proteins.
- Employed antisense oligodeoxynucleotide technology to inhibit PDGF and bFGF expression in vitro.
Main Results:
- All three tumor cell lines expressed PDGF (A- and B-chains) and bFGF mRNAs and proteins.
- Antisense inhibition of PDGF and bFGF significantly reduced the proliferation of all tested tumor cell lines in vitro.
- The extent of proliferation reduction varied among the different tumor types and growth factors.
Conclusions:
- Data suggest the presence of autocrine stimulatory loops involving PDGF and bFGF in neuroectodermal tumors.
- Blocking these autocrine loops with antisense technology demonstrates potential therapeutic efficacy in vitro.
- These findings highlight the potential therapeutic implications of targeting PDGF and bFGF in neuroectodermal tumors.